Wolverine Blend is a dual-peptide research formulation containing BPC-157 and TB-500. The two component peptides are studied in experimental systems examining peptide signalling, extracellular-matrix biology, endothelial pathways, cellular migration and cellular stress responses. This article reviews the published research relevant to those mechanisms and to the interaction of the two components.
The Wolverine Blend pairs two structurally distinct research peptides, BPC-157 and TB-500.
Quick reference
| Property | Value |
|---|---|
| Compound class | Synthetic pentadecapeptide + synthetic Thymosin β-4 fragment |
| Components | BPC-157 + TB-500 |
| Blend ratio | 10 mg BPC-157 + 10 mg TB-500 per vial |
| BPC-157 sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 amino acids) |
| TB-500 sequence | Ac-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln (8 amino acids, acetylated) |
| BPC-157 MW | 1419.53 g/mol |
| TB-500 MW | 889.04 g/mol (acetylated fragment) |
| BPC-157 CAS | 137525-51-0 |
| TB-500 CAS | 77591-33-4 (Thymosin β-4 fragment 17-23) |
| Form | Lyophilised white powder |
| Storage | 2–8°C refrigerated; −20°C for long-term lyophilised storage; protect from light and moisture |
Introduction
Wolverine Blend is a combination research formulation containing BPC-157 and TB-500. “Wolverine” is a colloquial formulation name rather than a scientific classification and should not be taken as implying a particular biological outcome.
BPC-157 is a synthetic 15-amino-acid peptide with preclinical literature involving endothelial, nitric-oxide-associated, gastrointestinal and cellular-stress pathways. TB-500 is a thymosin beta-4-derived peptide used in studies of actin-associated cytoskeletal organisation, cellular migration and endothelial signalling.
The rationale for studying the two components together is mechanistic comparison: they engage different experimental pathways. Combination-specific evidence is more limited than the literature for the individual components.
Mechanism of action
The two components are structurally and mechanistically distinct.
BPC-157 — endothelial and nitric-oxide-associated signalling
Published BPC-157 studies examine VEGF/VEGFR2-associated signalling, nitric-oxide pathways, FAK-paxillin signalling and gastrointestinal or cellular-stress endpoints in preclinical models.
TB-500 — actin-associated cytoskeletal dynamics
Published TB-500 and thymosin beta-4 studies examine G-actin binding, cytoskeletal organisation, cellular migration and endothelial-response endpoints.
Studying the two pathways together
A combined experimental system can be used to measure interactions between these pathways. Observations from the blend should be measured directly rather than inferred from the individual literatures.
Published research
The evidence base for the two individual peptides is broader than the evidence for the Wolverine formulation itself.
BPC-157 literature
Published BPC-157 research includes gastrointestinal, endothelial, musculoskeletal and neurological experimental models. Reported endpoints vary by study and remain predominantly preclinical.
TB-500 and thymosin beta-4 literature
Published work on TB-500 and full-length thymosin beta-4 includes actin dynamics, cellular migration, endothelial signalling, cardiovascular and epithelial experimental systems.
Combination research
Research specifically testing the two-component formulation is comparatively limited. Combination studies therefore require appropriate controls and should not assume additive or synergistic effects.
Limitations of current evidence
Most relevant evidence is preclinical and often concerns the individual components rather than the commercial blend. Findings should be interpreted within the methods and endpoints of each cited study.
References
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612-1632. doi:10.2174/138161211796196954
- Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology. 2016;14(8):857-865. doi:10.2174/1570159X13666160502153022
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012;12(1):37-51. doi:10.1517/14712598.2012.634793
- Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin β4 defined by active sites in short peptide sequences. The FASEB Journal. 2010;24(7):2144-2151. doi:10.1096/fj.09-142307
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010
- Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Annals of the New York Academy of Sciences. 2010;1194:179-189. doi:10.1111/j.1749-6632.2010.05492.x
Last updated: 4 June 2026